188
Participants
Start Date
January 31, 2013
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
NXN-462
Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
Placebo
Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
IRC Clinics, Towson
Compass Research LLC, Orlando
Meridien Research, Tampa
Meridien Research, Brooksville
FPA Clinical Research, Kissimmee
Nashville Neuroscience Group, Nashville
Trinity Clinical Research, Tullahoma
Medex Healthcare Research, Inc., Chicago
Lynn Health Science Institute, Oklahoma City
ClinRx Research LLC, Plano
Premier Research, Phoenix
Albuquerque Clinical Trials, Inc, Albuquerque
University of Southern California, Los Angeles
Northern California Research, Sacramento
Neurological Research Institute, Santa Monica
Suncoast Clinical Research, New Port Richey
Integrated Clinical Trial Services, West Des Moines
Michigan Head-Pain and Neurological Institute, Ann Arbor
Pain Specialist of Charleston, P.A., Mt. Pleasant
Progressive Clinical Research, San Antonio
Boston Clinical Trials, Boston
Clinical Trials of America, Inc., Hickory
Manna Research Vancouver, Vancouver
Manna Research, Inc., Toronto
Kells Medical Research Group - Manna Research, Pointe-Claire
Lead Sponsor
NeurAxon Inc.
INDUSTRY